Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive FVIII Replacement in Hemophilia A with Synovitis
NCT04784988Phase 4Completed
- Sponsor
- University of Naples Federico II
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rurioctocog alfa pegol in hemophilia A (2 arms), sponsored by University of Naples Federico II. Primary endpoint: Changes in synovial status at 6 months. Started Mar 2022; status: completed.
02
Drugs
rurioctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04784988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784988.